MSB and MESO Related Headlines
Go Back- Ryoncil® Profits Underpinning Substantial Growth Pipeline
- High Survival Rates With Ryoncil® in EIND Program Emphasize Importance of Earlier Use in Both Children and Adults With SR-aGvHD
- Ryoncil® Net Revenues Increase for the Quarter to US$30M
- Real-World Commercial Experience with Ryoncil® Shows 84% Survival of Children with SR-aGvHD After Completing 28-Days of Treatment
- FDA Acknowledges Effects on Pain Intensity Favor Rexlemestrocel-L, Confirms 12-Month Reduction in Back Pain Supports Product Efficacy
- Ryoncil® Sales Increase 60% in December Quarter to US$35.1M
- Mesoblast names Facchina as new chair, Bell to stay as director
- Mesoblast Announces Changes to Board of Directors' Leadership Roles
- Mesoblast Retires Senior Debt with Non-Dilutive, Lower Cost, Five-Year Credit Line
- Independent Study Presented at American Society of Hematology (ASH) Annual Meeting Concludes Remestemcel-L Superior to Ruxolitinib in Clinical Outcomes as Treatment for SR-aGvHD
- Mesoblast Participation at Piper Sandler Conference
- Mesoblast Trading Update at Annual General Meeting Highlights Continued Strong Growth in Ryoncil® Revenue
- Mesoblast and BMT CTN to Initiate Pivotal Trial of Ryoncil® as Part of First-Line Regimen in Adults with Severe Acute GVHD Refractory to Steroids
- Mesoblast to Meet With FDA Next Month to Discuss Rexlemestrocel-L and Opioid Cessation
- Ryoncil® Net Revenues Increase 69% in Second Quarter Post Launch
- Ryoncil® Revenues Increase 66% in Second Quarter Post Launch
- Ryoncil® Receives J-Code From Medicare & Medicaid Services (CMS) Facilitating Reimbursement and Broader Patient Access
- Mesoblast Cell Therapy Products are Designated U.S. Origin and Not Subject to Tariffs
- Successful Commercial Launch of Ryoncil® Highlighted at Global Healthcare Conferences
- Mesoblast Enters Into Option To Issue US$50 Million Convertible Notes
- Banner Year for Mesoblast With First FDA Product Approval and Successful Commercial Launch of Ryoncil®
- Successful Commercial Launch of Ryoncil®
- Mesoblast and FDA Align on Key Items for Revascor® Biologic License Application in Ischemic Heart Failure
- Mesoblast Maintains Momentum With FDA on Accelerated Approval Pathway for Revascor® in Ischemic Heart Failure and Label Extension for Ryoncil® in Adults With GvHD
MSB and MESO Related Press Releases
Go Back- Ryoncil® Profits Underpinning Substantial Growth Pipeline
- High Survival Rates With Ryoncil® in EIND Program Emphasize Importance of Earlier Use in Both Children and Adults With SR-aGvHD
- Ryoncil® Net Revenues Increase for the Quarter to US$30M
- Real-World Commercial Experience with Ryoncil® Shows 84% Survival of Children with SR-aGvHD After Completing 28-Days of Treatment
- FDA Acknowledges Effects on Pain Intensity Favor Rexlemestrocel-L, Confirms 12-Month Reduction in Back Pain Supports Product Efficacy
- Ryoncil® Sales Increase 60% in December Quarter to US$35.1M
- Mesoblast Announces Changes to Board of Directors' Leadership Roles
- Mesoblast Retires Senior Debt with Non-Dilutive, Lower Cost, Five-Year Credit Line
- Independent Study Presented at American Society of Hematology (ASH) Annual Meeting Concludes Remestemcel-L Superior to Ruxolitinib in Clinical Outcomes as Treatment for SR-aGvHD
- Mesoblast Participation at Piper Sandler Conference
- Mesoblast Trading Update at Annual General Meeting Highlights Continued Strong Growth in Ryoncil® Revenue
- Mesoblast and BMT CTN to Initiate Pivotal Trial of Ryoncil® as Part of First-Line Regimen in Adults with Severe Acute GVHD Refractory to Steroids
- Mesoblast to Meet With FDA Next Month to Discuss Rexlemestrocel-L and Opioid Cessation
- Ryoncil® Net Revenues Increase 69% in Second Quarter Post Launch
- Ryoncil® Revenues Increase 66% in Second Quarter Post Launch
- Ryoncil® Receives J-Code From Medicare & Medicaid Services (CMS) Facilitating Reimbursement and Broader Patient Access
- Mesoblast Cell Therapy Products are Designated U.S. Origin and Not Subject to Tariffs
- Successful Commercial Launch of Ryoncil® Highlighted at Global Healthcare Conferences
- Mesoblast Enters Into Option To Issue US$50 Million Convertible Notes
- Banner Year for Mesoblast With First FDA Product Approval and Successful Commercial Launch of Ryoncil®
- Successful Commercial Launch of Ryoncil®
- Mesoblast and FDA Align on Key Items for Revascor® Biologic License Application in Ischemic Heart Failure
- Mesoblast Maintains Momentum With FDA on Accelerated Approval Pathway for Revascor® in Ischemic Heart Failure and Label Extension for Ryoncil® in Adults With GvHD
